Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

584 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-09

Study Completion Date

2021-09-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized clinical trial for the comparison of the efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target LDL-C goal achievement in patients with recent ischemic stroke

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

NCT06186037

Coronary Artery Disease Dyslipidemias Primary Prevention

RECRUITING PHASE4

Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

NCT03169985

Coronary Artery Disease

ACTIVE_NOT_RECRUITING PHASE4

Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)

NCT00574782

Hypercholesterolemia Coronary Heart Disease Peripheral Vascular Disease +2 more

COMPLETED

Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

NCT06231966

Peripheral Artery Disease Polyvascular Disease

RECRUITING NA

Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI

NCT02859480

Coronary Artery Disease Coronary Disease Cardiovascular Diseases

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to compare the efficiency and safety on the target LDL-C goal achievement between rosuvastatin 10 mg plus ezetimibe 10 mg (rosuvastatin/ezetimibe 10/10 mg) once daily versus rosuvastatin 20 mg once daily in patients with recent ischemic stroke.

The target LDL-C goal achievement rate in patients with recent ischemic stroke has not been well studied. In particular, no clinical studies have been conducted comparing the efficacy and safety of low-dose rosuvastatin plus ezetimibe with high-dose rosuvastatin single agent for achieving target LDL-C levels.

In this trial, the investigators aim to compare the efficacy of the target LDL-C achievement between rosuvastatin 10 mg plus ezetimibe 10 mg (rosuvastatin/ezetimibe 10/10 mg) and rosuvastatin 20 mg in patients with recent ischemic stroke.

For this trial, more than 292 patients (584 total) per group will be enrolled.

Subjects who were satisfied with the inclusion/exclusion criteria of this trial and who agreed to participate in the clinical trial in writing were randomly assigned to a 1:1 ratio in the experimental group (the low-dose combination of rosuvastatin plus ezetimibe) and comparator group (high-dose rosuvastatin).

The duration of administration of the drug for clinical trials is 90 days (±14 days), and the efficacy and safety evaluation parameters are compared with baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke, Ischemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rosuvastatin/Ezetimibe 10/10mg

The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.

Group Type EXPERIMENTAL

Experimental: Rosuvastatin/Ezetimibe 10

Intervention Type DRUG

* Rosuvastatin/Ezetimibe 10/10mg
* orally administered once daily for 90 days

Rosuvastatin 20mg

The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days

Group Type ACTIVE_COMPARATOR

Active Comparator: Rosuvastatin 20mg

Intervention Type DRUG

* Rosuvastatin 20mg
* orally administered once daily for 90 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental: Rosuvastatin/Ezetimibe 10

* Rosuvastatin/Ezetimibe 10/10mg
* orally administered once daily for 90 days

Intervention Type DRUG

Active Comparator: Rosuvastatin 20mg

* Rosuvastatin 20mg
* orally administered once daily for 90 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rosuzet tab 10/10 mg Suvast tab 20mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with recent ischemic stroke who meet both 1) and 2) criteria below. 1) Patients with acute ischemic stroke confirmed by DWI(diffusion-weighted imaging)

This is satisfied by meeting at least one of the following two criteria:
1. Patients who sustained stroke symptoms for more than 24 hours and had acute ischemic lesions on DWI.
2. Patients with acute ischemic lesions in DWI who had improved symptoms within 24 hours.

2\) Patients with ischemic stroke within 90 days.
2. Statin therapy indicated according to the recommendations of the 2014 American Heart Association/American Stroke Association guidelines.

This is accomplished by meeting at least one of the following three criteria:
1. Patients with ischemic stroke due to arteriosclerosis and LDL-C ≥ 100 mg / dL. (Class I; Level of Evidence B)
2. Patients with ischemic stroke due to arteriosclerosis and LDL-C \<100 mg / dL. (Class I; Level of Evidence C)
3. Patients who require statin therapy due to other associated atherosclerotic cardiovascular disease. (Class I; Level of Evidence A).
3. Patients without statin dose within 28 days before ischemic stroke.
4. Patients who measured baseline LDL-C levels after an ischemic stroke. This is satisfied by meeting at least one of the following two criteria:

1. Patients who had a baseline LDL-C level before the onset of a recent ischemic stroke and started statin therapy.
2. Patients hospitalized with acute ischemic stroke who had baseline LDL-C levels after initiation of statin therapy should meet both of the following conditions:

1. Patients with LDL-C levels measured within 3 days after initiation of statin therapy
2. Patients in whom randomization and administration of the study drug can be administered within 7 days after baseline LDL-C measurement.
5. Adults over 19 years.
6. Those who voluntarily agreed in writing to the trial.

Exclusion Criteria

1. Planned vascular intervention before the end of trial
2. Significant hepatic dysfunction (Aspartate Aminotransferase or Alanine Aminotransferase \>120 IU/L)
3. Allergy or contraindication to rosuvastatin or ezetimibe
4. Alcohol or drug addiction
5. Pregnancy or breast-feeding
6. Severe anemia: Hb level \<10 g/dL for men and \<9 g/dL for women
7. Bleeding diathesis: platelet count \<100,000/μl or prothrombin time International Normalized Ratio \> 1·7
8. Inability or unwillingness to comply with study-related procedures
9. Employees of the investigator or study center, with direct involvement in the current study
10. Women unwilling to continue contraception during the study period
11. Participation in other clinical trials within three-month
12. Malignancy or other serious medical conditions with a life expectancy \<6 months
13. Treatment with protease inhibitors or cyclosporine
14. Patients with severe renal impairment (creatinine clearance \<30 mL / min)
15. Other reasons for ineligibility judged by investigators

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No